Effect of renal function on the pharmacokinetics of valsartan

Clinical Drug Investigation

Volumn 13, Issue 4, 1997, Pages 207-214

  Prasad, Pratapa ^a   Mangat, Surinder ^a   Choi, Les ^a   Chen, Sistine ^a   Chen, Bee ^a   Bernardo, Angelito ^b   Frame, David ^b   Sperelakis, Rita ^b   Lau, Alan ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; VALSARTAN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; MALE; NECK PAIN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SHOULDER PAIN; STATISTICAL ANALYSIS;

EID: 0030893274     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199713040-00005     Document Type: Article

References (8)

1. Criscione L, de Gasparo M, Bühlmayer P, et al. Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of angiotensin II AT 1-receptor subtype. Br J Pharmacol 1993; 110: 761-71
2. Oparil S, Dyke S, Harris, F, et al. The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension. Clin Ther 1996; 18: 797-810
3. Morice A, Lowry R, Brown M, et al. Angiotensin-converting enzyme and cough refelx. Lancet 1987; 2: 1116-8
4. Singer D, McGregor G. Angioneurotic oedema associated with two angiotensin converting enzyme inhibitors. BMJ 1986; 293: 1243
5. Flesch G, Müller P, Hell F, et al. Absolute bioavailability of valsartan in healthy volunteers. Eur J Drug Metab Pharmacokinet. In press
6. Brunner L, Powell M, Degan P, et al. A semi-automated analytical method for the determination of potential antihypertensive agents (CGP 48933 and/or CGP 48369) in human plasma using high performance liquid chromatography. Lab Robot Automat 1994; 6: 171-9
7. Sioufi A, Marfil F, Jaouen A, et al. The effect of age on the pharmacokinetics of valsartan. Eur J Drug Metab Pharmacokinet. In press
8. 14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose. Xenobiotica 1997; 27: 59-71